CATEGORIES

Skild Blog

Boston startup, Oncolinx wins $1 Million in 43North Competition

Oncolix.png

Oncolinx, in conjunction with the National Cancer Institute is developing the next generation of targeted cancer therapies: antibody-drug conjugates (ADCs). Oncolinx ADCs carry a patented, immune-activating drug payload called the Azonafide directly, and exclusively, to cancer cells, and not healthy cells, thereby avoiding many of the adverse side-effects of chemotherapy.

110 startups are one step closer to $1M - 43North 2015 business competition

Each year, the 43North business competition awards $5 million in cash prizes and services to some of the best and brightest entrepreneurs and startups from around the globe.  Awards include a one $1 million grand prize, six $500,000 prizes and four $250,000 prizes.

  • 1